The cost effectiveness of cardiac resynchronization therapy

Cardiac Resynchronization Therapy in Heart Failure

Volumn , Issue , 2011, Pages 137-141

  Kazi, Dhruv S ^a   Hlatky, Mark A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856078342     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (28)

1. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
2. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-880.
3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
4. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-2033.
5. Abraham WT, Young JB, Leon AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverterdefibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868.
6. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
7. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA. 2003;289: 2685-2694.
8. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:1454-1459.
9. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA.
10. Hlatky MA. Cost effectiveness of cardiac resynchronization therapy. J Am Coll Cardiol. 2005;46:2322-2324.
11. Basic Types of Economic Evaluation. In: Drummond MF, Torrance GW, O'Brien BJ, et al. Methods for Economic Evaluation of Health Care Programmes. 3rd. ed. New York, NY: Oxford University Press; 2005:7-26.
12. Oliver A. At The End Of The Beginning: Eliciting Cardinal Values For Health States. In: LSE Health and Social Care Discussion Paper Number 2 London, UK. : London School of Economics and Political Science; 2002. http://www.lse.ac.uk/collections/LSE Health And Social Care/pdf/DiscussionPaperSeries/DP2_2002.pdf . Last updated February 1, 2002. Accessed March 5, 2007.
13. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J. 2005;26:2681-2688.
14. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141:343-351.
15. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005;46:2311-2321.
16. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28:42-51.
17. Fox M, Anderson R, Dean J, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. In: Health Technology Assesment; 2007. http://www.ncchta.org/fullmono/mon1147.pdf. Accessed January 1, 2008.
18. Critical Assessment of Economic Evaluation. In: Drummond MF, SMJ, Torrance GW, O'Brien BJ, Stoddard GI, ed. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University press; 2005:27-54.
19. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines. Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE). Heart Rhythm Society 2007. (http://www.hrsonline.org/uploadDocs/HRSTaskForceRecsFull.pdf. Accessed August 30, 2007.)
20. Steinbrook R. The controversy over Guidant's implantable defibrillators. N Engl J Med. 2005;353:221-224.
21. Harris J. 'QALYfying the value of life.' J Med Ethics. 1987;13:117-123.
22. Williams A. The 'fair innings argument' deserves a fairer hearing! Comments by Alan Williams on Nord and Johannesson. Health Econ. 2001;10:583-585.
23. Nord E. Concerns for the worse off: fair innings versus severity. SocSciMed. 2005;60:257-263.
24. Pedone C, Grigioni F, Boriani G, et al. Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. Am J Cardiol. 2004; 93:371-373.
25. Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction. Evidence Report/ Technology Assessment No. 152 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023). Agency for Healthcare Research and Quality. AHRQ Publication No. 07-E009. Rockville, MD, 2007. http://www.ahrq.gov/clinic/tp/defibtp.htm.Accessed August 27, 2007.
26. McAlister FA, Tu JV, Newman A, et al. How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. Eur Heart J. 2006;27:239-323.
27. Grimm W, Sharkova J, Funck R, et al. How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy? Pacing Clin Electrophysiol. 2003;26:155-157.
28. Toma M, McAlister FA, Ezekowitz J, et al. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. Am J Cardiol.